Bernstein 'Positive' on Guardant Health (GH) Post 2025 Investor Day

Bernstein SocGen Group analyst Eve Burstein reiterated an Outperform rating and $60.00 price target on Guardant Health (NASDAQ: GH).

The analyst commented: "Guardant hosted their 2025 Investor Day on Wednesday (slides), highlighting progress since their last Investor Day in 2023 and laying out an updated roadmap across oncology, screening, and biopharma. The stock ended the day down 3.5% vs. the sector down 1%, but with better performance than many other SMID-cap diagnostics companies (e.g., NTRA -5%, TEM -6%, CAI -5%; TEM and CAI not covered).

We came out of Guardant’s Investor Day incrementally more positive on the company. We were glad to see management validate our hypothesis around their MCD goto-market strategy, and most intrigued by their discussion of using their platform to expand into other disease areas. The stock didn’t see a major positive move, and we believe some investors were expecting a slightly larger LRP increase / faster path to breakeven on Shield. However, for a company where consensus is still below the old LRP ($1.7B vs. $2B), we didn’t see a major guide increase as necessary. Additionally, if Shield can reach breakeven in 5 years, that will still be meaningfully faster than Exact - so nothing to sneeze at."

For an analyst ratings summary and ratings history on Guardant Health click here. For more ratings news on Guardant Health click here.

Shares of Guardant Health closed at $57.67 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters